Navigation Links
CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
Date:1/15/2008

Company to also Present at Stanford Group 13th Annual Healthcare Conference

SAN DIEGO, Jan. 15 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today that it will showcase its Cardiac Cryoablation System and its next generation ablation catheter, Quantum, at the Boston Atrial Fibrillation Symposium, January 17-19, 2008. CryoCor's products will be located at Booth 801.

In August 2007, the FDA approved the Cryoablation System for the treatment of right atrial flutter and CryoCor completed enrollment of its pivotal clinical study of the System for the treatment of atrial fibrillation. The Company has completed animal studies with Quantum, which is designed to significantly reduce the required time for an atrial fibrillation catheter ablation. CryoCor expects to enter human trials with Quantum in the second quarter of 2008.

Ed Brennan, Ph.D., President and Chief Executive Officer of CryoCor, said, "The Boston AF Symposium is the premier industry event focused on the treatment of atrial fibrillation, and as such, offers a tremendous forum to showcase our products to potential users. We look forward to the opportunity to increase the knowledge of our Cryoablation System and the unique advantages our technology provides physicians."

The Company also announced that Edward F. Brennan, President and Chief Executive Officer, and Gregory J. Tibbitts, Chief Financial Officer, are scheduled to present at the Stanford Group 13th Annual Healthcare Conference in Washington, D.C. on Thursday, January 17, 2008 at 7:45 a.m. ET at The Four Seasons Hotel.

A live Web cast and recording of the presentation will be available online from the investor relations page of the Company's corporate Web site at http://www.cryocor.com. The recording will remain available on CryoCor's Web site for at least 30 days following presentation.

About CryoCor

CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com

Forward Looking Statements

The statements in this press release that are not descriptions of historical facts are forward-looking statements that are subject to risks and uncertainties. These include statements related to the advantages and benefits provided by the Company's technology and the timing for when the Company expects to enter human trials with Quantum. Such statements are only predictions and reflect CryoCor's expectations and assumptions as of the date of this press release based on currently available operating, financial, and competitive information. The actual events or results may differ materially from those projected in such forward-looking statements due to a number of factors, including risks involved with CryoCor's technology, its development and the Company's anticipated timetable for developing and evaluating its technology; risks involved with the diagnosis and treatment of atrial arrhythmias; risks associated with the Company's dependence on patents and proprietary rights; risks associated with the Company's protection and enforcement of its patents and proprietary rights; risks associated with the development or availability of competitive products or technologies; risks associated with the Company's ability to maintain and achieve milestones under collaborative agreements and the other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update any of these forward- looking statements.

CryoCor, Inc.

Gregory J. Tibbitts

Chief Financial Officer

(858) 909-2200

gtibbitts@cryocor.com

The Ruth Group

Nick Laudico / Zack Kubow (investors)

(646) 536-7030 / 7020

nlaudico@theruthgroup.com

zkubow@theruthgroup.com

Jason Rando (media)

(646) 536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE CryoCor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CryoCor to Present at CIBC World Markets 18th Annual Healthcare Conference
2. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
3. Highlights of Economic and Business Growth in the Tampa Bay Region
4. Highlights of Economic and Business Growth in the Tampa Bay Region
5. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
6. Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007
7. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
8. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
9. Highlights of Economic and Business Growth in the Tampa Bay Region
10. Access Highlighted in Recent BusinessWeek Article
11. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a range ... place between the two entities said Poloz. Speaking ... Ottawa , he pointed to the country,s inflation ... federal government. "In ... "Both institutions have common economic goals, why not sit down ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
Breaking Biology Technology:
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
Breaking Biology News(10 mins):